文献速递血栓与止血

海曲泊帕治疗儿童免疫性血小板减少症的长期疗效与安全性

Long-term efficacy and safety of hetrombopag in paediatric patients with immune thrombocytopenia.
PubMed 文献 · Br J Haematol · 2026-01-19

本研究评估海曲泊帕在93例儿童免疫性血小板减少症(ITP)患者中的长期疗效与安全性,完全缓解率61.3%、总缓解率76.3%、无治疗缓解率52.1%,新诊断患者无治疗缓解率高于持续性或慢性患者,不良事件发生率37.6%且无严重不良事件。

要点

  • 海曲泊帕在儿童ITP中完全缓解率61.3%、总缓解率76.3%、无治疗缓解率52.1%。
  • 新诊断ITP患者无治疗缓解率高于持续性或慢性ITP患者。
  • 不良事件发生率37.6%,无严重不良事件报告。

核心结论

  • 海曲泊帕在儿童ITP患者中安全有效,可作为一线治疗失败后的可行选择。

研究设计与样本

  • 研究纳入93例接受海曲泊帕治疗的儿童ITP患者,评估完全缓解、缓解、总缓解、无缓解、持久缓解、复发和无治疗缓解率。

主要发现

  • 完全缓解率61.3%,缓解率15.1%,总缓解率76.3%,无缓解率23.7%,持久缓解率76.1%,复发率26.8%,无治疗缓解率52.1%。
  • 新诊断ITP患者的无治疗缓解率高于持续性或慢性ITP患者。
  • 9例从其他TPO-RA转换的患者中,7例在初始治疗期间达到总缓解,其中3例完全缓解、4例缓解。
  • 不良事件总发生率为37.6%,未报告严重不良事件。

临床怎么用

  • 海曲泊帕可用于一线治疗失败的儿童ITP患者,尤其是新诊断患者可能获得更高的无治疗缓解率。
  • 从其他TPO-RA转换治疗时,部分患者仍可获得完全缓解或缓解。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune thrombocytopenia (ITP) is an autoimmune disorder that occurs in children and adults, and it is characterized by a reduced platelet count. Hetrombopag, a novel thrombopoietin receptor agonist (TPO-RA) for second-line ITP treatment, lacks thorough efficacy and safety evaluation in paediatric patients. In this study, we assessed complete response (CR), response (R), overall response (OR), no response (NR), durable response (DR), relapse and treatment-free response (TFR) rates in 93 paediatric ITP patients who were treated with hetrombopag. The results demonstrated that the CR rate, R rate, OR rate, NR rate, DR rate, relapse rate and TFR rate were 61.3%, 15.1%, 76.3%, 23.7%, 76.1%, 26.8% and 52.1% respectively. Patients with newly diagnosed ITP exhibited a higher TFR rate than those with persistent or chronic ITP. Furthermore, among the nine patients who switched from other TPO-RAs, seven patients achieved OR during initial treatment, including three patients who achieved CR and four patients who achieved R. The overall incidence of adverse events was 37.6%, with no serious adverse events reported. Our findings highlight that hetrombopag is both safe and effective in paediatric patients and may serve as a viable option for patients for whom first-line therapy fails.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Wang JH, Yang Q, Duan SQ, et al. Long-term efficacy and safety of hetrombopag in paediatric patients with immune thrombocytopenia. Br J Haematol. 2026. PMID: 41554292. doi:10.1111/bjh.70309

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。